Policy & Regulation
Sigilon Therapeutics Augments Intellectual Property Portfolio with Recent US Patents
12 June 2019 - - US-based biopharmaceutical company Sigilon Therapeutics has added to its patent portfolio of US Patent Nos. 10,285,949 and 10,292,936, which are entitled "Modified alginates for cell encapsulation and cell therapy," the company said.
The patents are exclusively licensed to Sigilon and were granted to the Massachusetts Institute of Technology and The Children's Medical Center Corp.
These patents are based on foundational research by Sigilon Co-Founders Daniel G. Anderson, Ph.D., and Robert Langer, Sc.D. This research resulted in the invention of various chemically modified alginates that can protect implanted cells, biomaterials and medical devices from fibrosis and other immune responses to foreign bodies.
Sigilon's broad and deep patent portfolio covers all elements of Sigilon's product platform, from underlying chemistry and cells to encapsulation, as well as therapeutic uses in core diseases.
The portfolio consists of 18 patent families (exclusively licensed and Sigilon-owned), including seven US patents, five ex-US patents and more than 70 pending patent applications in all major markets.
Sigilon Therapeutics is a biopharmaceutical company creating functional cures for chronic diseases using its Shielded Living Therapeutics platform.
To create a Shielded Living Therapeutics product, we engineer novel human cells that we encase in a proprietary immune-shielding matrix and place in the body.
These Shielded Living Therapeutics products then produce therapeutic proteins in a programmable and durable fashion, without generating fibrosis or immune rejection.
Sigilon was founded and created by Flagship Pioneering in conjunction with Daniel G. Anderson, Ph.D., and Robert Langer, Sc.D., of the Massachusetts Institute of Technology.